Globus Medical (GMED) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Morgan Stanley Downgrades Globus Medical (GMED) to Equalweight
July 27, 2016 3:02 PM EDTMorgan Stanley downgraded Globus Medical (NYSE: GMED) from Overweight to Equalweight.
For an analyst ratings summary and ratings history on Globus Medical click here. For more ratings news on Globus Medical click here.
Shares of Globus Medical closed at $26.43 yesterday.
... MoreUPDATE: Canaccord Genuity Downgrades Globus Medical (GMED) to Hold
July 27, 2016 7:17 AM EDT(Updated - July 27, 2016 10:39 AM EDT)
Canaccord Genuity downgraded Globus Medical (NYSE: GMED) from Buy to Hold with a price target of $28.00 (from $30.00). Analyst Kyle Rose expressed concerns that its US business slow to regain momentum.
Rose explained, "We... More
Wells Fargo Upgrades Globus Medical (GMED) to Market Perform
July 27, 2016 7:16 AM EDTWells Fargo upgraded Globus Medical (NYSE: GMED) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Globus Medical click here. For more ratings news on Globus Medical click here.
Shares of Globus Medical closed at $26.43 yesterday.
... MoreLeerink Partners Downgrades Globus Medical (GMED) to Market Perform
July 27, 2016 7:12 AM EDTLeerink Partners downgraded Globus Medical (NYSE: GMED) from Outperform to Market Perform with a price target of $27.00 (from $29.00).
Analyst Richard Newitter commented, "We appreciate that GMED's above avg. EBITDA margin profile has held up despite decelerating 1H16 rev. growth, and acknowledge a better 2017 set-up as comps get easier and key investment initiatives like... More
